AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

DIMERIX LTD

0.240

+0.0052.13%

Volume:849.29K

Turnover:200.93K

Market Cap:144.10M

PE:-4.83

High:0.245

Open:0.245

Low:0.230

Close:0.235

52wk High:0.665

52wk Low:0.157

Shares:600.40M

Float Shares:467.70M

Volume Ratio:0.86

T/O Rate:0.18%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.050

EPS(LYR):-0.050

ROE:-594.54%

ROA:-29.36%

PB:-9.76

PE(LYR):-4.83

Loading ...

Overview Company News Filings

Mission Therapeutics: to Receive up to $292 Mln Plus Double-digit Tiered Royalties from Deal

THOMSON REUTERS

Dimerix Hits 'Major Milestone' With AU$10 Million Financing Package, Euroz Hartleys Says

MT Newswires Live

Australia's Dimerix Rises on Funding Boost and Pipeline Acquisition

Dimerix Acquires Therapeutic Asset from UK-Based Firm; Shares Up 8%

MT Newswires Live

Dimerix Secures AU$10 Million Loan Facility From Substantial Shareholder Associate; Shares Up 9%

MT Newswires Live

Dimerix Ltd-dimerix Expands Pipeline with Acquisition of Phase 2 Asset

THOMSON REUTERS

Dimerix Ltd - Initial A$10 Mln Loan Facility Secured

THOMSON REUTERS

Dimerix Requests Trading Halt

Dimerix - Trading Halt Requested Pending Non-dilutive Funding and Asset Acquisition Announcements

THOMSON REUTERS

Dimerix Expands Post-Trial Access to Kidney Disorder Drug for Eligible Patients

MT Newswires Live

Dimerix's Everest Deal Adds Value, Eases Funding Concerns, Euroz Hartleys Says

MT Newswires Live

BUZZ-Australia's Dimerix soars on commercialisation deal with Everest Medicines

Dimerix Ltd - Dimerix Licenses Dmx200 to Everest for China and Asia Region

THOMSON REUTERS

Everest Medicines - Agreement With Dimerix to Develop & Commercialize Dmx-200 in Greater China, South Korea and Southeast Asia

THOMSON REUTERS

Everest Medicines - Deal Includes $10 Mln Upfront, up to $30 Mln Development Milestones, $300 Mln Sales Milestones, 10%-15% Royalties

THOMSON REUTERS

Everest Medicines licenses Dimerix’s DMX-200 rights for Greater China, South Korea and Southeast Asia in deal worth up to USD 340 million

BRIEF-Dimerix Seeks Trading Halt

Dimerix - Trading Halt Requested Pending Out-Licensing Agreement Announcement

THOMSON REUTERS

Dimerix's Potential Non-Dilutive Funding May Lead to Ongoing Phase Three Trial Being Fully Funded, Euroz Hartleys Says

MT Newswires Live

BLINDED ASSESSMENT OF ACTION3 STATISTICAL ASSUMPTIONS COMPLETE

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/stock/DXB.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"DXB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"DXB.AU\",,,,,undefined,":{"symbol":"DXB.AU","market":"AU","secType":"STK","nameCN":"DIMERIX LTD","latestPrice":0.24,"timestamp":1789539120000,"preClose":0.235,"halted":0,"volume":849293,"delay":0,"changeRate":0.02127659574468087,"nameEN":"DIMERIX LTD","floatShares":467696880,"shares":600396776,"eps":-0.0497,"marketStatus":"Closed","change":0.005,"latestTime":"09-16 16:12:00 AEST","open":0.245,"high":0.245,"low":0.23,"amount":200934,"amplitude":0.06383,"askPrice":0.245,"askSize":93975,"bidPrice":0.235,"bidSize":42500,"shortable":3,"etf":0,"ttmEps":-0.0497,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1789603200000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":0.235,"openAndCloseTimeList":[[1789516800000,1789538400000]],"volumeRatio":0.864599,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"DXB.AU","preClose":0.235,"auctionPrice":0.24,"auctionVolume":346,"auctionTime":1789538945999,"referencePrice":0.24,"referenceTime":1789554603098,"auction":3,"marketStatus":"盘后竞价","timestamp":1789538945999}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"DXB.AU\",,,,,undefined,":{"symbol":"DXB.AU","floatShares":467696880,"roa":"-29.36%","roe":"-594.54%","lyrEps":-0.0497,"volumeRatio":0.864599,"shares":600396776,"dividePrice":0,"high":0.245,"amplitude":0.06383,"preClose":0.235,"low":0.23,"week52Low":0.157,"pbRate":"-9.76","psRate":"22.68","week52High":0.665,"institutionHeld":0,"latestPrice":0.24,"committee":-0.377175,"eps":-0.0497,"divideRate":0,"volume":849293,"delay":0,"ttmEps":-0.0497,"open":0.245,"prevYearClose":0.55,"prevWeekClose":0.25,"prevMonthClose":0.28,"prevQuarterClose":0.205,"fiveDayClose":0.26,"twentyDayClose":0.295,"sixtyDayClose":0.195,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DXB.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DXB.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DXB.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2652716408","title":"Mission Therapeutics: to Receive up to $292 Mln Plus Double-digit Tiered Royalties from Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2652716408","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652716408?lang=en_us&edition=fundamental","pubTime":"2026-07-17 15:32","pubTimestamp":1784273522,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260717:nFWN43I1WH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DXB.AU","BK7067","BK7508","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652064471","title":"Dimerix Hits 'Major Milestone' With AU$10 Million Financing Package, Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2652064471","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652064471?lang=en_us&edition=fundamental","pubTime":"2026-07-17 12:24","pubTimestamp":1784262255,"startTime":"0","endTime":"0","summary":"Dimerix's (ASX:DXB) AU$10 million financing package represents a \"major milestone\" as the company is now fully funded through the completion of its phase 3 focal segmental glomerulosclerosis study for","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","DXB.AU","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652476049","title":"Australia's Dimerix Rises on Funding Boost and Pipeline Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2652476049","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652476049?lang=en_us&edition=fundamental","pubTime":"2026-07-17 10:38","pubTimestamp":1784255930,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Dimerix rises on funding boost and pipeline acquisition** Shares of Australia's DimerixDXB.AXrise as much as 10.4% to A$0.265, their biggest intraday pct gain since July 6** Stock at its highest level since July 7** DXB stock set to mark its second consecutive session of gains, if trend holds** Stock up 2.1% in the week so far** The clinical stage biopharmaceutical firmsecuresa A$10 million  loan facility** Loan facility to support commercial manufacturing of DMX-200, a pill for kidney diseases, ahead of potential marketing approval submission and preparation for commercial launch, among others** Company separately says it expands pipeline with acquisition of DMX-652 for acute kidney injury** Near 4.7 million shares change hands, 1.5x the 30-day average** Stock has fallen 55.5% this year, including session moves","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260717:nL4N43J07T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","DXB.AU","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652047509","title":"Dimerix Acquires Therapeutic Asset from UK-Based Firm; Shares Up 8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2652047509","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652047509?lang=en_us&edition=fundamental","pubTime":"2026-07-17 09:45","pubTimestamp":1784252758,"startTime":"0","endTime":"0","summary":"Dimerix  acquired therapeutic asset DMX-652 for all indications from UK-based Mission Therapeutics for an upfront payment of $5 million, expanding the company's pipeline in rare kidney disease, according to a Friday filing with the Australian bourse.The company will also pay up to $47 million in deferred acquisition fee payable upon success of pre-defined clinical development milestones, $40 million on product marketing approval, $25 million on approval in a second indication, and up to $175 million on specific sales milestones, the filing said.The acquisition includes assignment of the composition-of-matter patent, an open Investigational New Drug application in the US with a phase two clinical trial protocol, a pharmaceutical-grade drug product for the trial, and all manufacturing methodology, per the filing.Dimerix shares rose 8% in morning trade on Friday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","DXB.AU","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652739754","title":"Dimerix Secures AU$10 Million Loan Facility From Substantial Shareholder Associate; Shares Up 9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2652739754","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652739754?lang=en_us&edition=fundamental","pubTime":"2026-07-17 08:39","pubTimestamp":1784248777,"startTime":"0","endTime":"0","summary":"Dimerix (ASX:DXB) entered into a loan facility agreement with Skiptan, an associate of substantial shareholder Peter Meurs, under which the lender has agreed to advance AU$10 million to the company at","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DMX","BK7501","DXB.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652420035","title":"Dimerix Ltd-dimerix Expands Pipeline with Acquisition of Phase 2 Asset","url":"https://stock-news.laohu8.com/highlight/detail?id=2652420035","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652420035?lang=en_us&edition=fundamental","pubTime":"2026-07-17 07:03","pubTimestamp":1784242987,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260716:nTUEWCH2R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","DXB.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652242008","title":"Dimerix Ltd - Initial A$10 Mln Loan Facility Secured","url":"https://stock-news.laohu8.com/highlight/detail?id=2652242008","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652242008?lang=en_us&edition=fundamental","pubTime":"2026-07-17 07:02","pubTimestamp":1784242924,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260716:nFWN43I20B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7501","BK7067","DXB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651314482","title":"Dimerix Requests Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2651314482","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651314482?lang=en_us&edition=fundamental","pubTime":"2026-07-15 06:43","pubTimestamp":1784068982,"startTime":"0","endTime":"0","summary":"BRIEF-Dimerix Requests Trading HaltJuly 15 (Reuters)-Dimerix LtdDXB.AX:TRADING HALT REQUESTED PENDING NON-DILUTIVE FUNDING AND ASSET ACQUISITION ANNOUNCEMENTSFurther company coverage:DXB.AX","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260714:nFWN43G19H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","BK7501","DXB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651482390","title":"Dimerix - Trading Halt Requested Pending Non-dilutive Funding and Asset Acquisition Announcements","url":"https://stock-news.laohu8.com/highlight/detail?id=2651482390","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651482390?lang=en_us&edition=fundamental","pubTime":"2026-07-15 06:42","pubTimestamp":1784068961,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260714:nFWN43G19H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","DXB.AU","BK7501","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650317943","title":"Dimerix Expands Post-Trial Access to Kidney Disorder Drug for Eligible Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2650317943","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650317943?lang=en_us&edition=fundamental","pubTime":"2026-07-09 11:52","pubTimestamp":1783569144,"startTime":"0","endTime":"0","summary":"Dimerix  said eligible patients with focal segmental glomerular sclerosis who complete treatment in its phase three clinical trial and open-label extension study will be able to continue receiving investigational therapy DMX-200 through post-trial access programs in key territories, according to a Thursday Australian bourse filing.The company said access will be provided to patients whose treating physicians determine that ongoing therapy is appropriate and that no suitable alternative is available through expanded access, compassionate use, special access, or other applicable regulatory pathways, subject to local regulations, per the filing.The company's commercial partners will handle market access and supply costs for DMX-200 in their territories, while it will assume these responsibilities in territories where no commercialization partner has been appointed, the filing added.The company's shares rose past 2% in recent Thursday trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["POST","BK7067","BK4212","BK7501","DXB.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644792742","title":"Dimerix's Everest Deal Adds Value, Eases Funding Concerns, Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2644792742","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644792742?lang=en_us&edition=fundamental","pubTime":"2026-06-17 11:08","pubTimestamp":1781665732,"startTime":"0","endTime":"0","summary":"Dimerix (ASX:DXB) has added incremental value through its licensing deal with Everest Medicines while strengthening its funding position and validating DMX-200's commercial potential, Euroz Hartleys s","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","BK7501","FSGS","DXB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643738819","title":"BUZZ-Australia's Dimerix soars on commercialisation deal with Everest Medicines","url":"https://stock-news.laohu8.com/highlight/detail?id=2643738819","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643738819?lang=en_us&edition=fundamental","pubTime":"2026-06-16 10:36","pubTimestamp":1781577361,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Dimerix soars on commercialisation deal with Everest Medicines** Shares of Australia's Dimerix DXB.AX rise as much as 51.5% to A$0.250, their highest since April 30** Clinical stage b","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nL6N42O05T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DXB.AU","01952","BK7067","BK1161","BK1574","BK7508","BK7501","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643784076","title":"Dimerix Ltd - Dimerix Licenses Dmx200 to Everest for China and Asia Region","url":"https://stock-news.laohu8.com/highlight/detail?id=2643784076","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643784076?lang=en_us&edition=fundamental","pubTime":"2026-06-16 08:21","pubTimestamp":1781569287,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260616:nFWN42N0LU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK1583","01952","BK1574","DXB.AU","BK7501","BK7067","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643814757","title":"Everest Medicines - Agreement With Dimerix to Develop & Commercialize Dmx-200 in Greater China, South Korea and Southeast Asia","url":"https://stock-news.laohu8.com/highlight/detail?id=2643814757","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643814757?lang=en_us&edition=fundamental","pubTime":"2026-06-16 06:56","pubTimestamp":1781564191,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nFWN42N0LL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DXB.AU","01952","BK7067","BK1161","BK1574","BK7508","BK7501","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643814207","title":"Everest Medicines - Deal Includes $10 Mln Upfront, up to $30 Mln Development Milestones, $300 Mln Sales Milestones, 10%-15% Royalties","url":"https://stock-news.laohu8.com/highlight/detail?id=2643814207","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643814207?lang=en_us&edition=fundamental","pubTime":"2026-06-16 06:56","pubTimestamp":1781564191,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nFWN42N0LL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","BK7508","DXB.AU","BK7501","BK7067","BK1583","01952","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643812867","title":"Everest Medicines licenses Dimerix’s DMX-200 rights for Greater China, South Korea and Southeast Asia in deal worth up to USD 340 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2643812867","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643812867?lang=en_us&edition=fundamental","pubTime":"2026-06-16 06:55","pubTimestamp":1781564151,"startTime":"0","endTime":"0","summary":"Everest Medicines licenses Dimerix’s DMX-200 rights for Greater China, South Korea and Southeast Asia in deal worth up to USD 340 million. Everest Medicines signed an exclusive license with Dimerix on June 16, 2026 to develop, commercialize DMX-200 in Greater China, South Korea, Southeast Asia.Upfront payment set at USD 10 million; development, regulatory milestones up to USD 30 million; sales milestones up to USD 300 million.Deal includes tiered royalties of 10% to 15% on future annual net sales.DMX-200 is a CCR2 small-molecule inhibitor in a pivotal Phase 3 trial for focal segmental glomerulosclerosis; holds FDA, EMA orphan-drug designations.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Everest Medicines Ltd. published the original","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nNDLTzzyl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1583","DXB.AU","BK7501","BK1161","BK1574","BK7067","01952","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643228788","title":"BRIEF-Dimerix Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2643228788","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643228788?lang=en_us&edition=fundamental","pubTime":"2026-06-15 07:54","pubTimestamp":1781481269,"startTime":"0","endTime":"0","summary":"BRIEF-Dimerix Seeks Trading Halt June 15 (Reuters) - Dimerix Ltd DXB.AX:TRADING HALT REQUESTED PENDING OUT-LICENSING AGREEMENT ANNOUNCEMENTFurther company coverage: DXB.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260614:nFWN42K0NK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","DXB.AU","BK7067","BK7501"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643285092","title":"Dimerix - Trading Halt Requested Pending Out-Licensing Agreement Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=2643285092","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643285092?lang=en_us&edition=fundamental","pubTime":"2026-06-15 07:14","pubTimestamp":1781478847,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260614:nFWN42K0NK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","DXB.AU","BK7501","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632699919","title":"Dimerix's Potential Non-Dilutive Funding May Lead to Ongoing Phase Three Trial Being Fully Funded, Euroz Hartleys Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2632699919","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632699919?lang=en_us&edition=fundamental","pubTime":"2026-05-01 10:45","pubTimestamp":1777603552,"startTime":"0","endTime":"0","summary":"Dimerix's  potential access to $50 million in non-dilutive funding could lead to it having up to AU$96.6 million in combined cash and non-dilutive funding available, which would be sufficient to fully fund the ongoing phase three trial and dispel any near-term capital raising risk, Euroz Hartleys said in a note on Thursday.It indicated this would not be traditional debt funding, but is rather repayable from future milestone payments and/or royalties.The commercial opportunity remains significant and unchanged, Euroz Hartleys added.The investment firm maintained its speculative buy rating on Dimerix with a price target of AU$1.35 per share.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","DBB","DXB.AU","BK7067","BK7501"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2630234053","title":"BLINDED ASSESSMENT OF ACTION3 STATISTICAL ASSUMPTIONS COMPLETE","url":"https://stock-news.laohu8.com/highlight/detail?id=2630234053","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630234053?lang=en_us&edition=fundamental","pubTime":"2026-04-28 10:17","pubTimestamp":1777342620,"startTime":"0","endTime":"0","summary":"An external statistical blinded review of ACTION3 data has achieved its objective by confirming that the study remains appropriately statistically powered  to demonstrate a treatment effect for the primary study endpoint of proteinuria; meaning that if DMX-200 continues to reduce proteinuria in trial patients as anticipated, then there is a >90% chance that the study will successfully show a statistically significant proteinuria treatment effect at the trial's conclusion. To maximise the likelihood of a successful study outcome and regulatory success, Dimerix and its commercialisation partners will continue the ACTION3 Phase 3 Study to the final proteinuria endpoint. As previously announced, the FDA has agreed that proteinuria is an appropriate endpoint for full regulatory approval for DMX-200 in ACTION3. Evidence from the PARASOL working group, together with the recent FDA approval of an FSGS therapy in the US based on the proteinuria endpoint, further supports proteinuria as the prim","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/blinded-assessment-of-action3-statistical-assumptions-complete-302755001.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7051","ARB.AU","DXB.AU","FSGS","BK7067","ARB","BK7501","BK7508"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":42,"code":"91000000","status":"200"}]}}